Administration of a High-Dose Erythropoietin-Stimulating Agent in Hemodialysis Patients is Associated with Late Arteriovenous Fistula Failure.

CONCLUSION: Patients with late AVF patency loss exhibit an association with a higher dose of ESA, although causality is unproven. Further study to elucidate potential mechanisms is warranted. PMID: 28540993 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/28540993?dopt=Abstract

Source: Yonsei Medical Journal - May 27, 2017 Category: Universities & Medical Training Authors: Jeong HY, Ko EJ, Kim SH, Lee MJ, Cho HJ, Yang DH, Lee SY Tags: Yonsei Med J Source Type: research